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Abstract
Background: Diabetes mellitus is strongly associated with cardiovascular dysfunction, derived in part from
impairment of sympathetic nervous system signaling. Glucose, insulin, and non-esterified fatty acids are potent
stimulants of sympathetic activity and norepinephrine (NE) release. We hypothesized that sustained hyperglycemia
in the high fat diet-fed streptozotocin (STZ) rat model of sustained hyperglycemia with insulin resistance would
exhibit progressive sympathetic nervous dysfunction in parallel with deteriorating myocardial systolic and/or
diastolic function.
Methods: Cardiac sympathetic nervous integrity was investigated in vivo via biodistribution of the positron
emission tomography radiotracer and NE analogue [
11C]meta-hydroxyephedrine ([
11C]HED). Cardiac systolic and
diastolic function was evaluated by echocardiography. Plasma and cardiac NE levels and NE reuptake transporter
(NET) expression were evaluated as correlative measurements.
Results: The animal model displays insulin resistance, sustained hyperglycemia, and progressive hypoinsulinemia.
After 8 weeks of persistent hyperglycemia, there was a significant 13-25% reduction in [
11C]HED retention in
myocardium of STZ-treated hyperglycemic but not euglycemic rats as compared to controls. There was a parallel
17% reduction in immunoblot density for NE reuptake transporter, a 1.2 fold and 2.5 fold elevation of cardiac and
plasma NE respectively, and no change in sympathetic nerve density. No change in ejection fraction or fractional
area change was detected by echocardiography. Reduced heart rate, prolonged mitral valve deceleration time, and
elevated transmitral early to atrial flow velocity ratio measured by pulse-wave Doppler in hyperglycemic rats
suggest diastolic impairment of the left ventricle.
Conclusions: Taken together, these data suggest that sustained hyperglycemia is associated with elevated
myocardial NE content and dysregulation of sympathetic nervous system signaling in the absence of systolic
impairment.
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Diabetes mellitus, hyperglycemia, and insulin resistance
confer a significantly greater risk of developing cardio-
vascular disease and heart failure [1]. The mechanisms
involved in the progression of ventricular dysfunction in
diabetes are diverse and unclear, with several pathways
having been implicated including disrupted metabolic
processes [2,3], glycation and interstitial fibrosis of myo-
cardium [4], oxidative stress and apoptosis [5], and
impairment of autonomic, particularly sympathetic, sig-
nal transduction [5-8].
The sympathetic nervous system is the primary extrin-
sic control of heart rate and contractility. Under stress,
release of the neurotransmitter norepinephrine (NE)
from sympathetic nerves enhances cardiac output [9].
Signaling is terminated by recovery of NE from the
synaptic cleft back into the neuron varicosity via the NE
reuptake transporter (NET) [10]. Dysregulation of sym-
pathetic innervation has been documented in congestive
heart failure [11], acute myocardial infarction [12], and
diabetes [13]. Enhanced sympathetic signaling partially
compensates for deteriorating myocardial function [9].
Glucose, insulin, and non-esterified fatty acids (NEFA)
are potent stimulants of NE and epinephrine release
[14,15]. Diabetic animals display reduced heart rate
variability, hypertension, and elevated plasma and tissue
levels of NE [16-20]. These animals develop systolic and
diastolic cardiac dysfunction over time [4,18,19,21]. The
frequent concurrence of diabetes with cardiac disease,
with each increasing the risk of developing the other,
implies a common pathogenesis [1]. It has been sug-
gested that sympathetic dysregulation may be involved
in such a process [1,7].
[
11C]meta-Hydroxyephedrine ([
11C]HED) has been
routinely applied in cardiac positron emission tomogra-
phy (PET) to interrogate sympathetic nervous integrity
in a myriad of clinical conditions including acute myo-
cardial infarction, cardiomyopathies, coronary artery dis-
ease, and heart failure [10,11]. Retention of [
11C]HED is
blocked by NET inhibitors and reduced by treatments
elevating synaptic NE [22,23]. Altered uptake of [
11C]
HED and other presynaptic tracers has been described
extensively in diabetic rats and mice [8,13], as well as
clinically [7]. The temporal progression of cardiac sym-
pathetic dysregulation and its relation to left ventricular
dysfunction remains unclear.
We hypothesized that sustained hyperglycemia would
contribute to cardiac sympathetic nervous dysfunction
which would manifest in parallel with deteriorating car-
diac systolic and diastolic function. The high fat diet-
fed, moderate dose streptozotocin (STZ) rat model of
sustained hyperglycemia with insulin resistance was seri-
ally characterized for metabolic and cardiac function,
and sympathetic nervous integrity was tested at 2 and 8
weeks of unregulated hyperglycemia using ex vivo bio-
distribution of [
11C]HED with NET expression and NE
levels measured concurrently. This combined approach
establishes an association between altered sympathetic
nervous signaling and functional abnormalities during
the progression of diabetes.
Methods
Drugs, chemicals, and radiochemistry
Desipramine hydrochloride, NE bitartrate, and STZ were
obtained from Sigma-Aldrich (Toronto, ON, Canada).
Drugs were dissolved in saline except STZ, which was
in tribasic citrate. Antibodies against rat NET
(AB5066P), tyrosine hydroxylase (AB1542) and GAPDH
(sc32233) were obtained from Chemicon/Millipore (Bill-
erca, MA, USA) and Santa Cruz Biotechnology (Santa
Cruz, CA, USA), respectively. Secondary horseradish
peroxidase conjugated IgG antibodies to mouse, rabbit
and sheep were from Santa Cruz (sc2314, sc32004) or
Abcam (ab6747, Cambridge, MA, USA). Histological
stains were from Richard Allan Scientific (Kalamazoo,
MI, USA). [
11C]HED was synthesized as previously
described and dissolved in 50:44:6 0.9% saline/water/
8.4% sodium bicarbonate (v/v/v) for injection [23]. High
radiochemical purity (> 99%) and specific activity (7.3-
55.5 GBq/μmol) were obtained.
Animal model
Animal experiments were conducted in accordance with
the Canadian Council on Animal Care, with approval of
the Animal Care Committee of the University of
Ottawa. Adult male Sprague-Dawley rats (200-250 g)
were obtained from Charles River Canada (Montreal,
QC, Canada) and housed in a temperature-controlled
animal facility under a 12 hour light/dark cycle with
food and water ad libitum. Rats were maintained on
high fat diet (Research Diets D12266B, New Brunswick,
NJ, USA) composed of (by kJ) 32% fat, 51% carbohy-
drate, and 17% protein. After two weeks of initial feed-
ing, a single intraperitoneal injection of moderate dose
STZ (45 mg/kg, n = 99) or vehicle (n = 44) was admi-
nistered [19,24-26]. Fed state blood glucose levels 2
weeks post-STZ were used to stratify treated rats by gly-
cemic state, with blood glucose levels exceeding 11 mM
considered to be hyperglycemic and the remainder con-
sidered as a STZ-treated euglycemic control group
[19,24]. Body weights, diet consumption, and blood mar-
kers were assessed in all animals. Whole heart weights
were determined at the conclusion of experiments and
expressed as a ratio to body weight. STZ- and vehicle-
treated rats were divided among several experimental
protocols (Table 1). An additional group (n = 5) were
Thackeray et al. Cardiovascular Diabetology 2011, 10:75
http://www.cardiab.com/content/10/1/75
Page 2 of 13fed standard rodent chow (Teklad 2019, Harlan Teklad,
Madison, WI, USA) for euglycemic clamp experiments.
Blood markers
Fed state blood glucose was tested weekly from the
saphenous vein using a glucose meter (AccuChek,
Roche Diagnostics, Laval, QC, Canada). Fasted (over-
night 8-12 h) plasma insulin, NEFA and triglyceride
were measured from trunk blood collected at 2 and 8
weeks post-STZ following decapitation by radioimmune
assay (Linco/Millipore, Billerca, MA, USA) or microplate
colorimetric assays (Biovision, Mountain View, CA,
USA), respectively.
Plasma and cardiac norepinephrine
Plasma and reconstituted heart samples were analyzed
for NE content using a modified inline capture, column-
switching high performance liquid chromatography pro-
cedure with electrochemical detection [23,27]. Briefly,
venous blood samples were centrifuged at 3000 × g to
separate plasma and filtered (0.2 μm) for injection.
Excised hearts were homogenized under 80/20 ethanol/
0.1 M formic acid, centrifuged at 82000 × g,a n ds u p e r -
natant evaporated in a rotary evaporator. The residue
containing NE was reconstituted under 0.1 M formic
acid and filtered. Samples were injected and NE
adsorbed onto a capture column (Direct Connect refill-
able guard column, 2 × 20 mm, Alltech, Deerfield, IL,
USA) containing activated aluminum oxide (Type WA4,
Sigma) under 1.5 M Tris, 0.05 M EDTA (2 mL), rinsed
with 10 mL of deionized water (1 mL/min), then eluted
by 5/95 methanol/50 mM ammonium formate, 0.27
mM EDTA, 0.346 mM octanesulfonic acid (pH 2.85, 1
mL/min) onto a cation exchange analytical column (Par-
tisil SCX, 250 × 4.6 mm, 10 μm, Phenomenex, Torrance,
CA, USA) for separation (NE retention time = 6.8 min),
and quantified by flow-through coulometric electroche-
mical detection (Coulochem III, ESA/Dionex, Chelms-
ford, MA, USA) with an applied voltage of 400 mV.
Amperage signals were integrated using the PeakSimple
Six Port Chromatography Data System and analysed
where area under the curve is representative of mass
NE. This procedure was validated using NE bitartrate
standards, demonstrating 95% recovery and linear repro-
ducibility in a physiological range (0.001-20 ng).
Oral glucose tolerance
Serial oral glucose tolerance tests were performed as
described elsewhere [25], at three intervals: prior to high
fat feeding, 2 weeks after STZ or vehicle injection, and 8
weeks after STZ or vehicle injection.
Euglycemic clamp
The hyperinsulinemic euglycemic clamp was performed
as described elsewhere [3]. Continuous iv infusion of
biosynthetic insulin (Novolin, 30 mU kg
-1 min
-1)w a s
counteracted by variable iv infusion of 20% glucose to
maintain glycemia at 5 mM. Rats were considered
clamped with three consecutive stable readings of blood
glucose levels and glucose infusion rate, within 120 min.
Indirect calorimetry
Calorimetric measures were obtained at 2 and 8 weeks
of diabetes using the 4-chamber Oxymax system
(Columbus Instruments, Columbus, OH, USA) as pre-
viously described [28]. Rats were sequestered in indivi-
dual 11.7 L calorimetry chambers with food and water
ad libitum for 24 h. Oxygen consumption, carbon diox-
ide production and respiratory exchange ratio (RER)
were measured five times per hour. RER provides an
index of carbohydrate versus fatty acid substrate utiliza-
tion [28].
Echocardiography
Serial echocardiography was carried out biweekly under
light anesthesia (1-2% isoflurane) using the Vevo 770
system (VisualSonics, Toronto, ON, Canada) and a 23.5
MHz probe [3]. All echocardiography studies were per-
formed and analyzed by a single operator. Parasternal
long and short axis views were recorded as sequential
ECG-gated M-mode sweeps (EKV-mode) to generate
two-dimensional cines of the left ventricle. Endocardial
and epicardial areas were traced on the two-dimensional
parasternal long axis cine and used to calculate left ven-
tricular volumes at end systole and end diastole. Calcu-
lations for stroke volume, percent ejection fraction (%
Table 1 Sample sizes of rat groups for individual
experiments
Streptozotocin
Controls Euglycemic Hyperglycemic
2 Weeks
HED* 6 4 4
HED + Desipramine* 4 3 4
Western Blot*
† 33 3
None*
† 35 6
2 Weeks Total 16 16 16
8 Weeks
HED* 8 9 14
HED + Desipramine* 6 6 5
OGTT + Western Blot*
† 33 3
Echocardiography*
† 57 8
Clamp + Histology* 3 5 4
Indirect Calorimetry* 3 0 3
8 Weeks Total 28 30 37
*Blood samples taken for measurement of biochemistry markers.
†Heart samples used for measurement of tissue norepinephrine.
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(%FAC) were completed using VisualSonics software.
Diastolic function was assessed using pulse-wave Dop-
pler across the mitral valve from the apical four cham-
ber view [3]. Early (E) and late (A) flow velocity as well
as mitral valve deceleration time provide an indication
of diastolic function.
[
11C]HED ex vivo biodistribution
Biodistribution studies were performed at 2 and 8 weeks
following STZ or vehicle injection in conscious animals,
as described previously [23,28]. Briefly, 50-75 MBq (0.2-
1.3 μg cold mass) of [
11C]HED was injected as a 0.1-0.3
mL bolus into a lateral tail vein of restrained rats. Ani-
mals were killed by decapitation 30 min after tracer
injection. A sample of trunk blood was collected. Hearts
were rapidly excised and dissected to right and left atria,
right and left ventricle free walls, and intraventricular
septum, and a portion of skeletal muscle (quadriceps
femoris) was taken as a reference tissue devoid of speci-
fic retention [23]. Samples were counted for radioactiv-
ity (decay corrected) in a gamma-counter along with 1%
standard dilutions of each [
11C]HED formulation. Total
tracer retention is expressed as percentage of injected
dose per gram of tissue, normalized to body weight (%
ID/g × BW). To delineate non-specific retention, a sub-
set of animals at 2 and 8 weeks post-STZ or vehicle was
injected with the NET inhibitor desipramine (10 mg/kg,
ip) 30 min prior to tracer administration. This value was
subtracted from the total [
11C]HED retention to deter-
mine specific retention.
Western immunoblotting
Hearts were removed and flash frozen in liquid nitrogen
following decapitation. Hearts were hand powdered
under liquid nitrogen and stored at -80°C until use.
Total cell lysate was prepared [6,29] and protein content
was determined by BCA assay. SDS-PAGE was carried
out using 8% polyacrylamide gels with 40 μgo fp r o t e i n
loaded for each sample. Protein was transferred to poly-
vinylidine difluoride membranes. Blocked membranes
were incubated in anti-NET (1:750) and anti-GAPDH
(1:2000) followed by secondary antibody incubation.
Protein was visualized by chemiluminescence Western
lighting kit (Perkin Elmer, Waltham, MA, USA) and the
Fluorchem HD Imaging System. Analysis was completed
with AlphaEase FC software normalizing NET immuno-
blot densities to GAPDH and expressed as a percentage
of controls.
Tyrosine Hydroxylase Immunostaining
To determine the relative sympathetic nerve density in
the myocardium, immunostaining for tyrosine hydroxy-
lase was carried out in paraffin-embedded short axis
heart sections as described elsewhere [30-32]. Briefly,
after antigen retrieval by citrate, slides were blocked in
normal horse serum and incubated for 96 hours at 4°C
with 1:100 anti-tyrosine hydroxylase. Slides were then
incubated with 1:100 anti-sheep HRP-conjugated sec-
ondary antibody and visualized using diaminobenzidine
reagent (Vector Labs). Six images from each section
were analysed using ImageJ software (National Institutes
of Health) to determine the area of positive staining as a
percentage of the total field of view.
Histopathology
Cardiomyocyte health was assessed by histopathology in
a subset of rats. Tissues were processed for histological
analysis as described elsewhere [4,19]. Hematoxylin and
eosin staining assessed cardiomyocyte morphology and
fibre size. Masson Trichrome staining was used to deter-
mine collagen deposition.
Statistics
All data are presented as mean ± standard deviation.
Differences between STZ-treated hyperglycemic, STZ-
treated euglycemic, and vehicle-treated control groups
were tested for significance by one-way analysis of var-
iance with Bonferroni’s post hoc test using SPSS 17.0
software. Indirect calorimetry data were tested with
repeated measures general linear model using SAS 9.0
software. Significance was considered at p < 0.05.
Results
Diabetic animal model
Injection of STZ was successful in inducing overt
hyperglycemia in 53.5% of treated rats (n = 53/99),
whereas 46 animals maintained normal glucose levels
(Figure 1A). After STZ injection, the average fed state
blood glucose concentration over 8 weeks in STZ-trea-
ted hyperglycemic, STZ-treated euglycemic, and con-
trol rats was 20.7 ± 8.7, 7.3 ± 2.7, and 6.5 ± 1.0 mM,
respectively. Body weights of all groups were similar
until the induction of diabetes, at which point STZ-
treated animals displayed stunted weight gain. As
diabetes progressed in hyperglycemic rats, further
depletion of weight gain was apparent (Figure 1B).
One week following treatment and for the remainder
of the experiment, STZ-treated hyperglycemic rats
tended to consume greater amounts of diet compared
to STZ-treated euglycemic and vehicle-treated controls
with an average per diem consumption of 568 ± 92,
518 ± 94, and 497 ± 83 kJ, respectively. Heart weight
was lower in STZ-treated hyperglycemic rats as com-
pared to controls. A higher heart to body weight ratio
was apparent in STZ-treated hyperglycemic rats as
compared to both STZ-treated euglycemic and vehicle-
treated controls (Table 2).
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Hyperglycemic rats displayed progressive hypoinsuline-
mia, with depletion of insulin levels at 8 weeks but not
at 2 weeks post-STZ. Fasted NEFA and triglyceride
levels were also significantly lower in STZ-treated
hyperglycemic rats as compared to both vehicle-treated
and STZ-treated euglycemic controls (Table 3).
Plasma and cardiac norepinephrine
Plasma NE concentrations were comparable between the
three groups of animals at baseline, but were 2.5 fold
higher in STZ-treated hyperglycemic rats at 8 weeks
(Table 3). HPLC analysis of cardiac samples revealed a
significant 1.4 fold elevation of NE in STZ-treated
hyperglycemic rats compared to vehicle-treated controls
at 2 weeks post-STZ, and a 1.2 fold elevation at 8 weeks
post-STZ. NE levels in STZ-treated euglycemic rats
were unchanged compared to vehicle-treated controls at
both time points (Figure 2).
Oral glucose tolerance
Prior to induction of diabetes by STZ, there was no dif-
ference in clearance of oral glucose load between groups
(Figure 3A). However, at 2 and 8 weeks following STZ
injection, animals with overt hyperglycemia displayed
impaired fasting glucose levels, higher peak glucose after
gavage, and a longer time to return to baseline (Figure
3B-C). STZ-treated euglycemic rats showed similar glu-
cose tolerance to vehicle-treated controls. The response
of insulin secretion to oral glucose load was ablated in
STZ-treated hyperglycemic rats and diminished in STZ-
treated euglycemic rats as compared to controls with
peak plasma insulin concentrations of 0.4 ± 0.1, 1.4 ±
1.0, and 3.8 ± 1.4 ng/mL at 8 weeks, respectively.
Euglycemic clamp
Rats at 8 weeks post-STZ were successfully clamped at 5
mM blood glucose during hyperinsulinemic euglycemic
clamp under anaesthesia. The glucose infusion rate
required to achieve steady state fasted blood glucose
concentration was 4.0 ± 2.0, 2.9 ± 1.8, 3.2 ± 0.4 mg kg
-1
min
-1 in STZ-treated hyperglycemic, STZ-treated eugly-
cemic, and vehicle treated control rats, respectively. The
infusion rates for all high fat-fed animals were signifi-
cantly lower than for chow-fed controls, which had a
glucose infusion rate of 25.0 ± 4.2 mg kg
-1 min
-1.
Indirect calorimetry
STZ-treated hyperglycemic rats oxidized a lower propor-
tion of carbohydrates as compared to vehicle-treated
controls after 8 weeks but not 2 weeks of hyperglycemia
(Figure 4A). There was a trend toward lower oxygen
consumption in STZ-treated hyperglycemic rats as com-
pared to controls (Figure 4B).
Echocardiography
Measures of systolic and diastolic cardiac function are
summarized in Table 4. STZ-treated hyperglycemic
A
B
A
B B
Figure 1 Blood glucose (A) and body weight (B) data from
high fat diet fed, moderate dose STZ-induced diabetic rats
over 8 weeks after STZ or vehicle administration. Mean ± SD. *
p < 0.05 to controls, † p < 0.05 to STZ euglycemic rats, one-way
ANOVA, Bonferroni post hoc.
Table 2 Terminal heart and body weights in STZ-treated hyperglycemic, STZ-treated euglycemic, and vehicle-treated
control rats
Control STZ, Euglycemic STZ, Hyperglycemic
2 Weeks 8 Weeks 2 Weeks 8 Weeks 2 Weeks 8 Weeks
Body Weight (g) 302.4 ± 26.5 584.7 ± 62.2 358.9 ± 22.7* 535.8 ± 43.9* 331.6 ± 30.1 424.6 ± 48.1*
†
Heart Weight (g) 0.89 ± 0.05 1.46 ± 0.17 1.13 ± 0.14* 1.38 ± 0.11 1.02 ± 0.06* 1.31 ± 0.12*
HW/BW (× 10
-3) 3.0 ± 0.2 2.5 ± 0.2 3.1 ± 0.3 2.6 ± 0.2 3.1 ± 0.2 3.1 ± 0.3*
†
Mean ± SD.
* p < 0.05 to age-matched control, † p < 0.05 to age-matched STZ, euglycemic, one-way ANOVA, Bonferroni post hoc
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euglycemic and control counterparts (Figure 5A).
There was no difference in percent LV ejection frac-
tion or fractional area change between groups (Figure
5B-C). However, STZ-treated hyperglycemic rats
demonstrated elevated mean mitral valve deceleration
time (Figure 5D) and E/A wave ratio as compared to
other groups (Table 4).
[
11C]HED ex vivo biodistribution
Retention of [
11C]HED was uniform in myocardium and
effectively blocked (81-86%) by pretreatment with desi-
pramine in all groups of animals. At 2 weeks post-STZ,
no difference in total or specific myocardial [
11C]HED
accumulation was observed between the groups (Figure
6A). Conversely, 8 weeks following induction of dia-
betes, hyperglycemic rats exhibited a significant decrease
in [
11C]HED retention as compared to STZ-treated
euglycemic and controls (Figure 6B). There was no
change in non-specific retention as defined by pretreat-
ment with desipramine. Percent change in total and spe-
cific cardiac tracer retention were similar at 13-26% and
12-26%, respectively (Table 5).
Table 3 Fasted levels of metabolic blood markers in STZ-treated hyperglycemic, STZ-treated euglycemic, and vehicle-
treated control rats
Control STZ, Euglycemic STZ, Hyperglycemic
Factor 2 Weeks 8 Weeks 2 Weeks 8 Weeks 2 Weeks 8 Weeks
Glucose (mM) 7.0 ± 1.2 6.3 ± 0.4 7.0 ± 1.1 5.9 ± 0.6 24.6 ± 7.2*
† 28.8 ± 5.1*
†
Insulin (ng/mL) 0.65 ± 0.41 1.36 ± 0.69 0.67 ± 0.66 0.79 ± 0.57 0.78 ± 0.46 0.33 ± 0.33*
†
NEFA (nM) 0.20 ± 0.10 0.40 ± 0.13 0.31 ± 0.05 0.20 ± 0.12* 0.30 ± 0.22 0.24 ± 0.14*
Triglyceride (nM) 0.79 ± 0.05 0.81 ± 0.35 0.67 ± 0.17 0.66 ± 0.14 0.80 ± 0.45 0.55 ± 0.29*
NE (ng/mL) 0.10 ± 0.05 0.11 ± 0.06 0.10 ± 0.14 0.10 ± 0.03 0.10 ± 0.06 0.24 ± 0.09*
†
Mean ± SD.
* p < 0.05 to age-matched control, † p < 0.05 to age-matched STZ, euglycemic, one-way ANOVA, Bonferroni post hoc
Figure 2 Cardiac NE content at 2 and 8 weeks after STZ or
vehicle administration. Mean ± SD. * p < 0.05 to controls, † p<
0.05 to euglycemic, one-way ANOVA, Bonferroni post hoc.
A
B
C
A
B B
C C
Figure 3 Oral glucose tolerance testing at baseline (A) and at 2
(B) and 8 weeks after STZ or vehicle administration (C). Mean ±
SD. * p < 0.05 to controls, † p < 0.05 to STZ euglycemic rats, one-
way ANOVA, Bonferroni post hoc.
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Immunoblots for NET resulted in consistent protein
bands at 76 and 78 kDa, as per the manufacturer’sd o c -
umentation (Figure 7A). Relative NET expression nor-
malized to GAPDH was significantly reduced in cardiac
lysate of STZ-treated hyperglycemic rats by 17% com-
pared to controls and by 15% to STZ-treated euglycemic
rats (Figure 7B).
Tyrosine Hydroxylase Immunostaining
Tyrosine-hydroxylase-positive nerve endings were iden-
tified within the left ventricle in each group (Figure 8A).
Quantitative analysis revealed no difference in staining
between STZ-treated hyperglycemic, STZ-treated eugly-
cemic, and vehicle-treated controls, suggesting main-
tained sympathetic innervation (Figure 8B).
Histopathology
There were no differences in cardiomyocyte morphology
between STZ-treated hyperglycemic, STZ-treated eugly-
cemic, and control rats (Figure 9). Masson Trichrome
staining revealed no change in collagen content between
groups (Figure 9).
Discussion
In the present article, we describe a progressive dete-
rioration of cardiac sympathetic nervous integrity in the
presence of diastolic left ventricular abnormalities in a
rat model of insulin resistance with uncontrolled hyper-
glycemia. A reduction of 12-26% in myocardial [
11C]
A
B
A
B
Figure 4 Indirect calorimetry assessment of oxygen
consumption (A) and respiratory exchange ratio (B) at 2 and 8
weeks after STZ or vehicle administration. Mean ± SD. * p < 0.05
to controls, repeated measures, general linear model.
Table 4 Echocardiography parameters in STZ-treated hyperglycemic, STZ-treated euglycemic, and vehicle treated
control rats at 2, 4, 6, and 8 weeks after STZ
Control STZ, Euglycemic STZ, Hyperglycemic
2 Weeks 4 Weeks 6 Weeks 8 Weeks 2 Weeks 4 Weeks 6 Weeks 8 Weeks 2 Weeks 4 Weeks 6 Weeks 8 Weeks
EV (d) (μL) 477 ± 135 477 ± 65 431 ± 90 353 ± 43 570 ± 47 457 ± 100 400 ± 67 363 ± 35 435 ± 103 497 ± 117 483 ± 80 369 ± 111
EV (s) (μL) 199 ± 49 184 ± 72 137 ± 35 128 ± 19 192 ± 33 134 ± 39 160 ± 9 95 ± 23 189 ± 57 182 ± 42 162 ± 36 119 ± 37
SV (μL) 278 ± 122 293 ± 30 293 ± 58 225 ± 27 379 ± 81 323 ± 118 240 ± 76 268 ± 21 262 ± 57 314 ± 86 321 ± 52 250 ± 79
CO (mL/min) 105 ± 52 106 ± 15 112 ± 16 81 ± 11 138 ± 47 113 ± 37 93 ± 18 100 ± 13 82 ± 23 91 ± 18 94 ± 19 69 ± 22
IVCT (ms) 62 ± 5 79 ± 13 70 ± 6 64 ± 9 84 ± 5 74 ± 7 65 ± 7 73 ± 6 83 ± 14 81 ± 14 83 ± 15 78 ± 6
IVRT (ms) 22 ± 4 33 ± 5 25 ± 8 32 ± 7 23 ± 0 30 ± 5 31 ± 2 24 ± 6 27 ± 6 25 ± 4 34 ± 15 33 ± 5
A (cm/s) 62 ± 22 77 ± 13 85 ± 33 77 ± 25 59 ± 6 83 ± 22 65 ± 17 97 ± 23 50 ± 13 65 ± 21*
† 58 ± 39 69 ± 19*
†
E (cm/s) 98 ± 5 118 ± 23 92 ± 26 98 ± 19 105 ± 5 119 ± 22 92 ± 8 125 ± 42 92 ± 18 104 ± 24 98 ± 28 99 ± 21
E/A Ratio 1.7 ± 0.5 1.6 ± 0.3 1.2 ± 0.4 1.3 ± 0.3 1.8 ± 0.1 1.5 ± 0.2 1.4 ± 0.3 1.3 ± 0.2 1.9 ± 0.6 1.7 ± 0.3 2.0 ± 1.0 1.5 ± 0.3
* p < 0.05 to controls, † p < 0.05 to euglycemic, one-way ANOVA, Bonferroni post hoc
(EV = endocardial volume at diastole (d) or systole (s); SV = stroke volume; CO = cardiac output; IVCT = intraventricular contraction time; IVRT = isovolumic
relaxation time; A = transmitral atrial (late) filling velocity; E = transmitral early filling velocity)
Calculations:
EV (d) = (4π/3) × (Endo Major (d)/2) × ((Endo Area (d))/π (Endo Major (d)/2))
2
EV (s) = (4π/3) × (Endo Major (s)/2) × ((Endo Area (s))/π (Endo Major (s)/2))
2
SV = EV(d) - EV (s)
EF = SV/EV (d) × 100%
FAC = (Endo Area (d) - Endo Area (s))/Endo Area (d) × 100%
CO = SV × Heart Rate
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relative cardiac NET expression and an increase in
plasma and cardiac NE content at 8 weeks of diabetes
with no change in sympathetic nerve density. While dia-
stolic function appears to be abnormal, left ventricular
ejection fraction is maintained, and histology is
unchanged, indicating preserved systolic function.
Diabetic Animal Model
The animal model used in these experiments mimics
certain aspects of clinical type 2 diabetes, exhibiting
insulin resistance, sustained hyperglycemia, and progres-
sive hypoinsulinemia [24-26]. The STZ-treated hypergly-
cemic rats show reduced insulin, NEFA and triglyceride
levels as compared to both sets of controls at 8 weeks,
inconsistent with some previous reports describing ele-
vated lipid levels [25]. This may reflect the longer dura-
tion of insulin resistance and diabetes examined in the
present study, 2 to 8 weeks post-STZ as compared to 3-
7 days. Glucose tolerance deteriorates over time follow-
ing STZ injection, as evidenced by greater impairment
of fasting glucose and higher peak glucose levels
attained in hyperglycemic rats following oral glucose
loading. Zhang and colleagues demonstrated a similar
result with intravenous glucose tolerance testing in this
animal model [24]. High fat feeding has been shown to
induce insulin resistance in rodents, a result that is
reflected by the current data. Insulin resistance and glu-
cose intolerance is further supported by the indirect
calorimetry data, which demonstrate fatty acid as the
preferred energy substrate in STZ-treated hyperglycemic
rats, as in other diabetic animal models and in patients
[33,34]. These diabetic rats lack the obesity and pro-
longed hyperinsulinemia commonly associated with type
2 diabetes, but permit the evaluation of elevated blood
glucose in the presence of high fat diet-induced insulin
resistance. Moreover, the inclusion of STZ-treated
euglycemic rats, which show a modest development of
insulin insufficiency at 8 weeks, suggests that hypergly-
cemia is the predominant influencing factor in sympa-
thetic dysregulation for this model.
Cardiac Dysfunction in Diabetic Rats
Development of cardiac dysfunction has been documen-
ted in several animal models of type 1 and type 2 dia-
betes, with decline in systolic and diastolic function, as
AB
CD
Figure 5 Serial echocardiographic assessment of left ventricle ejection fraction (A), fractional area change (B), heart rate (C), and
mitral valve deceleration time (D) at 2, 4, 6, and 8 weeks after STZ or vehicle administration. Mean ± SD. * p < 0.05 to controls, † p<
0.05 to euglycemic, one-way ANOVA, Bonferroni post hoc.
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Page 8 of 13well as in cardiac output [2,3,18,21,35]. In the present
experiments, hyperglycemic rats exhibit some indicators
of impaired diastolic function, as measured by consis-
tently higher E/A ratio and prolonged mitral valve
deceleration time. Diastolic dysfunction is a common
early manifestation of heart disease in diabetic animal
models [35] and patients [36]. This is comparable to
previous reports in the present animal model and in the
Zucker Diabetic Fatty rat model of type 2 diabetes,
which exhibit reduced heart rate, prolonged isovolumic
relaxation time and increased chamber stiffness
[3,18,19,36]. Because diastolic parameters are influenced
by the time spent in diastole, the reduction of heart rate
observed in STZ-treated hyperglycemic rats poses a
complication in interpreting these results. A recent
study of STZ-induced diabetes in Wistar rats established
that autonomic impairment, as measured by reduced
baroreflex sensitivity to phenylephrine, was associated
with diastolic dysfunction, characterized both by echo-
cardiographic and left ventricular hemodynamics [21].
Still, further investigation of diastolic function in the
present case is warranted.
Sympathetic Nervous Integrity
In the current study, there is a conclusive reduction in
presynaptic sympathetic nervous integrity, consistent
with previous reports in animal models of diabetes.
Reduced tracer accumulation is present despite an
increase in heart to body weight ratio compared to
STZ-treated euglycemic and vehicle-treated controls,
which in the absence of a physiological alteration to
sympathetic nervous integrity would be instead expected
to increase. This result suggests that reduced [
11C]HED
retention reflects abnormal sympathetic innervation
rather than an artifact of tissue weight. Schmid and col-
leagues have shown a progressive regional reduction of
[
11C]HED retention in distal left ventricle in intravenous
high dose STZ-induced type 1 diabetic rats as compared
to non-diabetic controls, associated with elevated NE at
6 months of diabetes and depletion of nerve growth fac-
tor (NGF) at 9 months [13]. These data suggest that dia-
betic autonomic neuropathy associated with reduced
cardiac NE content is not present at 8 weeks of diabetes,
rather displaying dysregulated sympathetic signaling
characterized by elevated NE release. Recently, small
animal single photon emission computed tomography
(SPECT) imaging using the [
11C]HED analogue [
123I]
meta-iodobenzylguanidine (MIBG) in db/db type 2 dia-
betic mice demonstrated maintained tracer uptake with
enhanced washout rate [8]. These findings are consistent
with elevated sympathetic activity without a pronounced
decrease in NET density; that is, enhanced local release
A
B
A
B
Figure 6 Ex vivo biodistribution of [
11C]HED 30 min post-tracer
injection in cardiac regions and skeletal muscle at 2 (A) and 8
weeks (B) after STZ or vehicle administration. Mean ± SD. * p <
0.05 to controls, † p < 0.05 to euglycemic, one-way ANOVA,
Bonferroni post hoc.
Table 5 Percent change in total and specific cardiac HED retention compared to vehicle treated controls
Group Right Atrium Left Atrium Right Ventricle Left Ventricle Septum
Total Retention
STZ, Euglycemic -5 ± 1 -8 ± 1 +2 ± 0 +5 ± 1 +5 ± 1
STZ, Hyperglycemic -24 ± 4 -26 ± 4 -18 ± 3 -13 ± 3 -13 ± 3
Specific Retention*
STZ, Euglycemic -6 ± 1 -12 ± 1 +1 ± 0 +5 ± 1 +5 ± 1
STZ, Hyperglycemic -24 ± 4 -26 ± 4 -19 ± 3 -12 ± 3 -13 ± 3
Mean ± SD.
*Specific Retention (SR) = Total Retention (TR) - Non-Specific Retention (NSR) [desipramine]
% Change = TRSTZ -T R control /TRcontrol
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Page 9 of 13of catecholamines and vesicle-packaged MIBG. Further-
more, Kiyono and colleagues have suggested that differ-
ential factors influence MIBG retention in rat models of
type 1 and type 2 diabetes [37,38]. Specifically, in intra-
venous STZ-induced type 1 diabetic rats, MIBG
retention was moderately reduced compared to controls,
paralleled by a twofold increase in cardiac NE concen-
tration and no change in NET [38]. By contrast, in Goto
Kakizaki non-obese type 2 diabetic rats, the global and
regional decrease in MIBG uptake was correlated to no
change in cardiac or plasma NE but a 30-45% reduction
in NET Bmax as assessed by [
3H]desipramine binding
assay [37]. In the present study, after 8 weeks of uncon-
trolled hyperglycemia, a modest decrease in apparent
NET expression is paralleled by a significant 20% eleva-
tion of cardiac NE, 250% elevation of plasma NE, and a
significant 12-25% reduction in [
11C]HED retention.
Importantly, the consistent tyrosine hydroxylase immu-
nostaining between groups indicates that sympathetic
denervation is not responsible for reduced [
11C]HED
retention. Persistently elevated catecholamines evoke
downregulation of cardiomyocyte b-adrenoceptor
expression in parallel with NET [39]. We and others
have demonstrated that adrenoceptors in diabetic myo-
cardium are reduced by 30-40% [40] and can be
restored by insulin treatment [6]. This has important
functional consequences, manifesting as impaired cal-
cium transport by sarcoplasmic/endoplasmic reticulum
calcium ATPase (SERCA) and loss of excitation-contrac-
tion coupling [21,41].
Sympathetic Nervous System and Heart Disease
Cardiac deterioration is a common endpoint for most
diabetic animal models and the most common cause of
death in diabetic patients [1]. Studies in isolated per-
fused hearts of STZ-induced diabetic rats have shown
reduced cardiac output, depressed cardiac b-adrenocep-
tor expression, and partial restoration by treatment with
the b-blocker metoprolol [2]. Indeed, Mongillo and col-
leagues propose that presynaptic sympathetic integrity is
proportional to glucose uptake in heart failure [42], sug-
gesting a complementary value in [
11C]HED retention to
myocardial viability. Considered with the present experi-
ments, these data imply a role for sympathetic dysregu-
lation in the progression of cardiac disease in diabetic
rats. Continuous b-adrenergic stimulation by infusion of
isoproterenol generates cardiac hypertrophy, bradycar-
dia, and slowed end-diastolic relaxation rates [43]. NET
knockout mice display elevated cardiac NE, hypertension
and tachycardia [44]. Conversely, overexpression of NET
has been shown to ameliorate downregulation of b-adre-
noceptors and SERCA, and restore ventricle diameters
and systolic function in experimental heart failure [45].
Catecholamines have been implicated in the develop-
ment of cardiovascular dysfunction, acting to dysregu-
late calcium transport, alter angiotensin II signaling
[4,46], increase reactive oxygen species [47], and exert
direct toxicity by conversion to quinones [48]. Recent
work has suggested that abnormal heart rate and heart
A
B B
NET
GAPDH
CH E CHECHE
78kDa
36kDa
Figure 7 Representative immunoblots for NET and GAPDH (A).
Relative quantification of immunoblot density between groups 8
weeks after STZ or vehicle administration (B). Mean ± SD. * p < 0.05
to controls, † p < 0.05 to euglycemic, two-tailed t-test.
A
B B
Control STZ, Euglycemic STZ, Hyperglycemic
30μm
Figure 8 Sympathetic nerve density assessment by tyrosine
hydroxylase immunostaining of left ventricle sections at 8
weeks after STZ or vehicle administration. Representative slides
from vehicle-treated control, STZ-treated euglycemic, and STZ-
treated hyperglycemic rats (A). 20 × magnification; white
arrowheads indicate tyrosine-hydroxylase positive nerve terminals.
Relative sympathetic nerve density as percentage tyrosine-
hydroxylase-positive area per field of view (B).
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Page 10 of 13rate variability in diabetic rats can be normalized by
renal denervation using phenol, though conclusions are
preliminary [20]. Cardiac autonomic neuropathy is a
common complication of diabetes, associated with
depletion of cardiac NE stores and reduced neurotro-
phin expression. It is conceivable that a period of sym-
pathetic hyperactivity precedes denervation and may
provide opportunity for neuronal rescue by NGF ther-
apy, as suggested elsewhere [32].
Potential of PET in Diabetic Heart Disease
The current experiments suggest that non-invasive PET
measures of cardiac sympathetic nervous integrity may
have important prognostic value for cardiac events in
diabetes. In the ADMIRE HF trial, Jacobson and collea-
gues demonstrated that patients with the lowest heart to
mediastinal ratio in MIBG scintigraphy had ten times
higher cardiac mortality than those with preserved neu-
ronal uptake [49]. Similarly, the Detection of Ischemia
in Asymptomatic Diabetics (DIAD) trial attempted to
identify patients at risk of developing cardiac dysfunc-
tion by analyzing myocardial perfusion in diabetic
patients with preserved ejection fraction [50]. Patients
who showed impaired perfusion were more likely to
incur a cardiac event. The present results suggest that
analysis of sympathetic nervous integrity may provide a
more sensitive marker of early cardiac dysfunction in
diabetes. A 3 year follow-up [
11C]HED imaging study in
type 1 diabetic patients demonstrated recovery of [
11C]
HED retention in patients with good glycemic control,
and greater defect size with reduced tracer uptake in
patients with poor glycemic control [7]. These studies
indicate the potential for molecular imaging to stratify
diabetic patients for cardiac risk.
Limitations
A limitation in the use of [
11C]HED biodistribution to
define sympathetic nervous system defects is the inabil-
ity to delineate the mechanistic cause of the abnormal-
ity. Sympathetic nervous dysfunction can manifest both
at the nerve terminals, which can be assessed by [
11C]
H E DP E T ,o ri nt h ec e n t r a ln e r v o u ss y s t e mw i t he f f e r -
ent nerve traffic, which cannot. Previous work has
demonstrated attenuation of sympathoadrenal responses,
originating from higher brain centers [51]. Moreover,
direct measurement of neurotrophins was not underta-
ken in this study, though maintained sympathetic nerve
density and elevated cardiac and plasma NE suggest
functional sympathetic neurons. While the present work
confirms abnormal cardiac sympathetic nervous signal-
ing in sustained hyperglycemia, further research is war-
ranted to more closely define the mechanism of this
defect and its relation to diastolic dysfunction.
Conclusions
Sustained hyperglycemia with insulin resistance in the
high fat fed moderate dose STZ rat is associated with
cardiac sympathetic dysregulation manifested by
H
&
E
M
a
s
s
o
n
Control STZ Euglycemic STZ Hyperglycemic
Figure 9 Histopathology of left ventricle at 8 weeks after STZ or vehicle administration. Hematoxylin and eosin (H&E) and Masson
Trichrome staining in control, STZ euglycemic, and STZ hyperglycemic rats. 20 × magnification.
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Page 11 of 13elevated plasma and cardiac NE, reduced NET expres-
sion, and depleted [
11C]HED retention with maintained
sympathetic nerve density. These findings were observed
in conjunction with echocardiographic indicators of dia-
stolic dysfunction and in the absence of systolic dysfunc-
tion of the diabetic myocardium. Taken together, these
results suggest that non-invasive [
11C]HED PET may be
a useful tool to monitor cardiac sympathetic nervous
dysfunction and guide glycemic therapy in diabetic
patients.
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